Syn-Ake, INCI name dipeptide diaminobutyroyl benzylamide diacetate, is a cosmetic peptide modeled on waglerin-1, a component of the venom of the Temple viper. It targets the same clinical goal as Argireline by a genuinely different route.
This guide situates Syn-Ake within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.
Where it comes from
Waglerin-1 is a peptide found in the venom of Tropidolaemus wagleri, the Temple viper. It causes paralysis by antagonizing the muscle-type nicotinic acetylcholine receptor at the neuromuscular junction — acetylcholine is released normally, but the receptor cannot respond to it.
Venom-derived drug design is a legitimate and productive field: venoms are refined libraries of highly selective molecules acting on nerve and muscle, and several approved medications originate from them.
Syn-Ake is a synthetic dipeptide modeled on the active region of waglerin-1. It is worth stating clearly for patients: it contains no venom. It is a laboratory-made molecule inspired by a natural sequence, and the marketing framing around snake venom is considerably more dramatic than the chemistry warrants.
A post-synaptic mechanism
The mechanistic distinction from the SNAP-25 mimics is real and worth understanding.
Argireline and SNAP-8 act presynaptically, interfering with the machinery that releases acetylcholine from the nerve terminal. Syn-Ake acts postsynaptically, at the receptor on the muscle cell that acetylcholine binds to.
Both aim to reduce muscle contraction, approaching from opposite sides of the synapse. Because the mechanisms are independent, formulations sometimes combine them on the reasoning that the effects should be additive — a coherent rationale, if the underlying premise holds.
The same limitation applies
Syn-Ake faces the identical practical constraint as the rest of this category. Its target — the neuromuscular junction of facial muscle — lies well beneath the skin surface, and a topical product must cross the stratum corneum, epidermis and dermis to reach it.
Syn-Ake has one advantage: as a dipeptide, it is considerably smaller than the hexa- and octapeptides, and smaller molecules penetrate skin more readily. That is a genuine point in its favour relative to Argireline and SNAP-8.
Whether that translates into pharmacologically meaningful receptor occupancy at facial neuromuscular junctions remains unestablished. Reported studies describe modest wrinkle-depth reductions on instrumental measures, with the familiar limitations of small samples, manufacturer sponsorship and hydration confounding.
The realistic expectation is the same as for the category: subtle improvement in fine lines with sustained use, not an alternative to injection.
Status
Syn-Ake is a cosmetic ingredient, not a drug, and is not approved to treat any condition. It is well tolerated at cosmetic concentrations.
For clinicians, the practical value in knowing these three peptides is being able to answer the patient who asks whether a serum can substitute for their neuromodulator appointment. The accurate answer — that the mechanisms are real, the delivery is the problem, and the effects are subtle — is more persuasive than dismissal, and it is true. Our peptides for skin guide covers the broader topical category.
Learn peptides the right way
Empire Medical Training's Peptide Therapy Master Course is a CME-accredited program covering cosmetic peptide mechanisms and topical delivery, patient selection, monitoring, regulatory status, and compliant sourcing — taught by board-certified physicians. Available in person and via livestream. It is also Course 1 of Empire’s Peptide Therapy Certification, which adds business, marketing and healthcare-law training, a documented case series and a final exam.
Explore the Certification →